In vitro synergistic anti-prion effect of cholesterol ester modulators in combination with chlorpromazine and quinacrine

Central European Journal of Biology

Volumn 5, Issue 2, 2010, Pages 151-165

  Orrù, Christina D ^a   Cannas, M Dolores ^a   Vascellari, Sarah ^a   Angius, Fabrizio ^a   Cocco, Pier Luigi ^a   Norfo, Claudia ^a   Mandas, Antonella ^a   la Colla, Paolo ^a   Diaz, Giacomo ^a   Dessì, Sandra ^a   Pani, Alessandra ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cholesterol esters; Cholesterol metabolism; Drug combinations; Prion inhibitors; Prions

Indexed keywords

OVIS ARIES;

EID: 77952096872     PISSN: 1895104X     EISSN: 16443632     Source Type: Journal    
DOI: 10.2478/s11535-009-0070-9     Document Type: Article

References (38)

1. Prusiner S. B., Prions, Proc. Natl. Acad. Sci. USA, 1998, 95, 13363-13383.
2. Trevitt C. R., Collinge J., A systematic review of prion therapeutics in experimental models, Brain, 2006, 129, 2241-2265.
3. Doh-ura K., Ishikawa K., Murakami-Kubo I., Sasaki K., Mohri S., Race R., et al., Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models, J. Virol., 2004, 78, 4999-5006.
4. Bone I., Belton L., Walker A. S., Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK, Eur. J. Neurol., 2008, 15, 458-464.
5. Love R., Old drugs to treat new variant Creutzfeldt-Jakob disease, Lancet, 2001, 358, 563-574.
6. Stewart L. A., Rydzewska L. H. M., Keogh G. F., Knight R. S. G., Systematic review of therapeutic interventions in human prion disease, Neurology, 2008, 70, 1272-1281.
7. Collinge J., Gorham M., Hudson F., Kennedy A., Keogh G., Pal S., et al., Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial, Lancet Neurol., 2009, 8, 334-344.
8. Geschwind M. D., Clinical trials for prion disease: difficult challenges, but hope for the future, Lancet Neurol., 2009, 8, 304-306.
9. CJD (Creutzfeldt-Jakob disease) quinacrine study. (accessed March 4, 2009). http://clinicaltrials.gov/ct2/show/NCT00183092.
10. Kocisko D., Caughey B., Morrey J. D., Race R. E., Enhanced antiscrapie effect using combination drug treatment, Antimicrob. Agents Chemother., 2006, 50, 3447-3449.
11. Pani A., Abete C., Norfo C., Mulas C., Putzolu M., Laconi S., et al., Cholesterol metabolism in brain and skin fibroblasts from Sarda breed sheep with scrapie resistant or susceptible genotype, Am. J. Infect. Dis., 2007, 3, 143-150.
12. Pani A., Abete C., Norfo C., Mulas C., Putzolu M., Laconi S., et al., Accumulation of CE in ex vivo lymphocytes from scrapie-susceptible sheep and in scrapie-infected mouse neuroblastoma cell lines, Am. J. Infect. Dis., 2007, 3, 165-168.
13. Orrù C. D., Abete C., Cannas M. D., Mulas C., Norfo C., Mandas A., et al., ACAT-1, Cav-1 and PrP expression in scrapie susceptible and resistant sheep, Cent. Eur. J. Biol., 2010, 5, 31-37.
14. Pani A., Norfo C., Abete C., Mulas C., Putzolu M., Laconi S., et al., Anti-prion activity of cholesterol esterification modulators: a comparative study in ex vivo sheep fibroblasts and lymphocytes and in mouse neuroblastoma cell lines, Antimicrob. Agents Chemother., 2007, 51, 4141-4147.
15. Doh-ura K., Iwaki T., Caughey B., Lysosomotropic Agents and Cysteine Protease Inhibitors Inhibit Scrapie-Associated Prion Protein Accumulation, J. Virol., 2000, 74, 4894-4897.
16. Caughey B., Raymond G. J., Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells, J. Virol., 1993, 67, 643-650.
17. Caughey B., Brown K., Raymond G. J., Katzenstein G. E., Thresher W., Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red, J. Virol., 1994, 68, 2135-2141.
18. Kocisko D. A., Engel A. L., Harbuck K., Arnold K. M., Olsen E. A., Raymond L. D., et al., Comparison of protease-resistant prion protein inhibitors in cell cultures infected with two strains of mouse and sheep scrapie, Neurosci. Lett., 2005, 388, 106-111.
19. Suhnel J., Evaluation of synergism or antagonism for the combined action of antiviral agents, Antiv. Res., 1990, 13, 23-40.
20. Pani A., Batetta B., Putzolu M., Sanna F., Spano O., Piras S., et al., MDR1, cholesterol esterification and cell growth: a comparative study in normal and multidrug-resistant KB cell lines, Cell. Mol. Life Sci., 2000, 57, 1094-1102.
21. Greenspan P., Fowler S. D., Spectrofluorometric studies of the lipid probe, Nile red, J. Lipid Res., 1985, 26, 781-789.
22. Diaz G., Batetta B., Sanna F., Uda S., Reali C., Angius F., et al., Lipid droplet changes in proliferating and quiescent 3T3 fibroblasts, Histochem. Cell Biol., 2008, 129, 611-621.
23. Kocisko D. A., Baron G. S., Rubenstein R., Chen J., Kuizon S., Caughey B., New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products, J. Virol., 2003, 77, 10288-10296.
24. Pani A., Dessì S., (Eds.), Cell Growth and Cholesterol Esters, New York: Landes Bioscence & Kluwer Academic Press Publishers, 2004.
25. Batetta B., Mulas M. F., Sanna F., Putzolu M., Bonatesta R. R., Casperi-Campani A., et al., Role of cholesterol ester pathway in the control of cell cycle in human aortic smooth muscle cells, FASEB J., 2003, 17, 746-748.
26. Varghese Z., Fernando R., Moorhead J. F., Powis S. H., Ruan X. Z., Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts, Am. J. Physiol. Renal Physiol., 2005, 289, 43-48.
27. Freeman D. A., Romero A., Effects of troglitazone on intracellular cholesterol distribution and cholesterol-dependent cell functions in MA-10 Leydig tumor cells, Biochem. Pharmacol., 2003, 66, 307-313.
28. Debry P., Nash E. A., Neklason D. W., Metherall J. E., Role of multidrug resistance P-glycoproteins in cholesterol esterification, J. Biol. Chem., 1997, 272, 1026-1031.
29. Butler J. D., Banchette-Mackie J., Golden E., O'Neill R. R., Carstea G., Roff C. F., et al., Progesterone blocks cholesterol translocation from lysosomes, J. Biol. Chem., 1992, 267, 23797-23805.
30. Barret A., Tagliavini F., Forloni G., Bate C., Salmona M., Colombo L., et al., Evaluation of quinacrine treatment for prion diseases, J. Virol., 2003, 77, 8462-8469.
31. Klingenstein R., Lober S., Kujala P., Godsave S., Leliveld S. R., Gmeiner P., et al., Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments, J. Neurochem., 2006, 98, 748-759.
32. FernØ J., Skrede S., O Vik-Mo A., Havic B., Steen V. D., Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs, BMC Neuroscience, 2006, 7, 69-80.
33. Vik-Mo A. O., Ferno J., Skrede S., Steen V. M., Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells, BMC Pharmacol., 2009, 9, 10.
34. Kumar R., McClain D., Young R., Carlson G. A., Cholesterol transporter ATP-binding cassette A1 (ABCA1) is elevated in prion disease and affects PrPC and PrPSc concentrations in cultured cells, J. Gen. Virol., 2008, 89, 1525-1532.
35. Bach C., Gilch S., Rost R., Greenwood A. D., Horsch M., Hajj G. N., et al., Prion-induced activation of cholesterogenic gene expression by Srebp2 in neuronal cells, J. Biol. Chem., 2009, 284, 31260-31269.
36. Taylor D. R., Hooper N. M., Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-β proteins, Sem. Cell. Develop. Biol., 2007, 18, 638-648.
37. Bate C., Tayebi M., Williams A., Cholesterol esterification reduces the neurotoxicity of prions, Neuropharmacology, 2008, 54, 1247-1253.
38. Ghaemmaghami S., Phuan P. W., Perkins B., Ullman J., May B. C., Cohen F. E., et al., Cell division modulates prion accumulation in cultured cells, Proc. Natl. Acad. Sci. USA., 2007, 104, 17971-17976.